CTRI/2021/10/037231CompletedPhase 3
A Monocentric, Assesor Blind, Randomized, Controlled, Before And After Use Clinical Study To Evaluate And Compare The Efficacy Of Topically Applied Moisturizer In Improving Symptoms Associated With Cutaneous Xerosis On The Legs, Over A Period Of 4 Weeks
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Cipla Ltd
- Enrollment
- 31
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1. 1.Subjects with clinical diagnosis of skin xerosis associated with symptoms and signs such as erythema, desquamation, pruritus/itching, lichenification etc. (as verified by the Investigator using ODS scoring and SRRC Grading)
- •2.Subjects between 18-65 years (both inclusive) of age.
- •3.Subjects with no disease state or physical condition that the Investigator believes could interfere with the interpretation of the data.
- •4.Subjects free of excessive hair, cuts, abrasions, fissures, wounds, lacerations, or any other active skin conditions that as per the investigator could interfere with interpretation of the data.
- •5.Subjects willing not to use any other soap/cleanser/cream/lotion/perfume/any skin care products/any other treatments on the affected area during the study, except investigational product and their own regular cleanser.
- •6.Subjects willing not to remove hair of the affected area by waxing/shaving/using stone/etc or any depilatory (hair removing) within 3 days before the scheduled study visit.
- •7.Subject willing and able to fulfil the study requirements and schedule
- •8.Subject willing to provide written informed consent and are able to read, speak, write, and understand English or Hindi or any other vernacular language.
- •9.Female of childbearing potential willing to undergo urine pregnancy test [self-declared by subject on screening visit and test to be done on Visit 2, Baseline visit (Day 0) and Visit 6, Day 28]
- •10.Female of childbearing potential, who is not sexually active, or who is using an effective contraceptive method for at least one month before the beginning of the study, and throughout the study.
Exclusion Criteria
- •1.Subjects who are pregnant or lactating or who are planning to become pregnant during the study.
- •2.Subjects who have started, stopped or changed his/her hormonal treatment (including contraceptive pill) in the previous one month prior to the study.
- •3.Subjects having known hypersensitivity to the study product or its constituents.
- •4.Any significant medical condition that would interfere with the participation in the trial, as per opinion of the Investigator.
- •5.Any concomitant medical/surgical condition or using medication which may harm the subject or may interfere with the study assessments, as per opinion of the Investigator.
- •6.Any topical or systemic treatment which in the opinion of the investigator might counter or influence the trial aim within the last 4 weeks prior to participation in the study and during the study.
- •7.Subjects with any of the following conditions present on the test area: viral lesions, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, ulcers and wounds.
- •8.Having participated in the last 30 days before screening or currently participating in another clinical study.
- •9.Unable to be contacted by phone in case of emergency.
Investigators
Similar Trials
Active, not recruiting
Phase 1
A study to investigate the degree to which a new product, RB Lotion, is safe, well tolerated and acceptable for treating Radiation Induced Skin Reactions (RISR) in subjects being treated with external beam radiotherapy, compared with their usual care.Radiation Induced Skin Reactions (RISR)MedDRA version: 20.0 Level: LLT Classification code 10061103 Term: Dermatitis radiation System Organ Class: 100000004863EUCTR2015-002258-10-GBDermal Laboratories Ltd10
Recruiting
Phase 2
A single (assessor) blinded, randomized, parallel-group, monotherapy trial to evaluate the pharmacokinetics and safety of tralokinumab in children (age 6 to <12 years) with moderate to-severe atopic dermatitis.Atopic dermatitisNL-OMON53683eo Pharma6
Active, not recruiting
Phase 1
Tralokinumab monotherapy for children with moderate-to-severe atopic dermatitis. TRAPEDS 1 (TRAlokinumab PEDiatric trial no. 1)Atopic dermatitisEUCTR2021-005573-12-NLEO Pharma A/S53
Not yet recruiting
Phase 3
A Phase III clinical study to evaluate efficacy and safety of GeneSys Insulin GlargineCTRI/2023/03/050804GeneSys Biologics Pvt. Ltd.
Not yet recruiting
Unknown
Effect of the use of personal learning plans among trained first year medical students- a randomized trialCTRI/2023/08/056861Dr Rituparna Basu